Valproate 치료를 받는 간질환아에서 체중증가와 영향을 주는 인자 = Valproate-associated weight gain and potential predictors in children with epilepsy

다국어 초록 (Multilingual Abstract)

Purpose : The purpose of this study was to determine the incidence and potential predictors of weight gain in older children and teens treated with valproate (VPA) for epilepsy.
Methods : Sixty-five subjects aged 8 to 17 years of age, who began VPA treatment between January 1, 2001, and December 31, 2004, and who had documented weight and height measurements at medication initiation and at least one follow-up visit were retrospectively identified. Exclusion criteria were follow-up <6 months, discontinuation of VPA within 6 months, and concurrent therapy with medication known to affect weight (such as topiramate, carbamazepin). Body mass index (BMI) was calculated at initiation and either discontinuation of VPA or last follow-up and stratified into four categories: group 1, underweight ＜5%; group 2, appropriate 5-85%; group 3, potentially overweight 85-95%; group 4, overweight ＞95%.
Results : Twenty-eight subjects (77.8%) remained within their same category and eight (22.2%) moved up at least one category. Weight gain (increase in BMI difference) was observed in 72.2% of the 36 subjects treated with VPA. Three factors, neurocognitive status (P=0.017), seizure type (P=0.001) and duration of VPA treatment (P=0.035) were identified to be significant predictors of BMI difference.
Conclusion : VPA induces weight gain in children and teens with epilepsy. These factors which are normal neurocognitive status, primary generalized type and duration of VPA treatment over the 12 months were predictors for an increase of weight gain. Therefore potential weight gain should be discussed with patients before the initiation of therapy and BMI should be monitored closely.

국문 초록 (Abstract)

목 적 : VPA치료를 받는 소아 청소년기 간질환자들에서 체중증가의 비율과 체중증가에 관련되는 예측 인자를 알아보고자 하였다.
방 법 : 2001년 1월 1일부터 2004년 12월 31일까지 VPA 치료를 받기 시작한 8세에서 17세까지의 환아를 대상으로 하였다. 제외기준은 치료 시작후 6개월 이내 치료가 중단된 경우, 체중에 영향을 주는 약물을 병합한 경우 등이었다. VPA 치료 시작시와 치료 시작 후 한번이상 재방문시에 체중과 신장이 측정되어 두 시점에서 BMI를 측정한 후 대상 환아들을 백분위수에 따라 4가지의 BMI군으로 분류하여 BMI군의 상승여부를 조사했으며 체중증가율을 의미하는 BMI difference를 계산하였다. 또한 체중증가에 영향을 미치는 여러 인자들을 회귀분석 하였다.
결 과 : 전체 36명중 총 8명의 환아가 VPA 치료전보다 최소 한 단계 이상의 BMI군의 상승변화를 보였으며 대상환아의 72.2%에서 체중증가(BMI difference의 증가)를 나타내었다. 신경정신 발달(P=0.017), 간질 형태(P=0.001), 투약기간(P=0.035)은 통계적으로 유의한 체중증가에 영향을 미치는 예측인자였다.
결 론 : VPA는 간질 환아에서 체중증가를 유발하며 정상 신경정신 발달, 전신 발작형 간질, 12개월 이상의 투약기간이 체중증가의 예측인자로 생각된다. 따라서 VPA 치료를 받는 소아 간질환자에서는 치료 시작 전에 VPA로 인한 체중증가의 가능성을 고려하여 치료 받는 중 BMI의 지속적인 감시측정이 필요할 것으로 생각된다.

참고문헌 (Reference)

• 1 Corman CL, "Weight gain in epileptic patients during treatment with valproic acid: A retrospective study" 24 : 240-244, 1997
• 2 Dinesen H, "Weight gain during treatment with valproate" 70 : 65-69, 1984
• 3 Demir E, "Weight gain associated with valproate in children" 22 : 361-364, 2000
• 4 Biton V, "Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy" 56 : 172-177, 2001
• 5 Wirrell EC, "Valproic acid-associated weight gain in older children and teens with epilepsy" 28 : 126-129, 2003
• 6 Isojarvi JI, "Valproate, lamotrigen, and insulin-mediated risks in women with epilepsy" 43 : 446-451, 1998
• 7 Turnbull DM, "Valproate causes metabolic disturbance in normal man" 49 : 405-410, 1986
• 8 Vorum H, "Valproate and palmitate binding to serum albumin in valproate-treated patients: Relation to obesity" 16 : 55-64, 1993
• 9 Panksepp J, "The role of GABA in the ventro medical hypothalamic regulation of food intake" 5 : 453-460, 1980
• 10 Kim IC, "The pattern of weight gain and change of peripheral serum lipid profiles in idiopathic epileptic children treated with valproate" 10 : 81-86, 2002
• 11 Dornhorst A, "The evaluation of sodium valproate treatment of Nelson's syndrome" 56 : 985-991, 1983
• 12 Astrup AV, "Sodium valproate promotes obesity by reducing energy expenditure" 13 : 126-, 1983
• 13 Yoon WS, "Serum leptin levels in epileptic children with anticonvulsant medication." 6 : 285-289, 1999
• 14 Verrotti A, "Serum leptin changes in epileptic patients who gain weight after therapy with valproic acid" 53 : 230-232, 1999
• 15 Considine RV, "Serum immuno- reactive leptin concentrations in normal-weight and obese humans" 34 : 292-295, 1996
• 16 Shoenfeld WN, "Pediatric obesity. An overview of etiology and treatment" 44 : 339-361, 1997
• 17 Isojarvi JIT, "Obesity and endocrine disorders in women taking valproate for epilepsy" 39 : 579-584, 1996
• 18 Breum L, "Metabolic changes during treatment with valproate in humans: Implication for untoward weight gain" 41 : 29-37, 1992
• 19 Wirrell EC, "Long-term psychosocial outcome in typical absence epilepsy: Sometimes a wolf in sheeps' clothing" 151 : 152-158, 1997
• 20 Maffei M, "Leptin level is human and Rodent: measurement of plasma leptin and ob gene RNA in obese and weight-reduced subjects" 1 : 1155-1161, 1995
• 21 Rogers V, "Inhibition of gluconeogenesis by so dium valproate and its metabolites in rat hepatocytes" 15 : 759-765, 1985
• 22 Egger J, "Effects of sodium valproate in 100 children with special reference to weight" 283 : 577-581, 1981
• 23 Austin JK, "Childhood epilepsy and asthma: Comparison of quality of life" 35 : 608-615, 1994
• 24 Kim SJ, "Change of body weight according to antiepileptic drugs in children with epilepsy: Valproic Acid vs. Topiramate" 11 : 68-72, 2003